Published online 4 July 2008
Haematologica, Vol 93, Issue 9, 1426-1428 doi:10.3324/haematol.11564
Copyright © 2008 by Ferrata Storti Foundation
Reinhard Zenhäusern1 ,
Mathew Simcock2 ,
Alois Gratwohl3 ,
Urs Hess4 ,
Mario Bargetzi5 ,
Andreas Tobler6 on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
Patients received rituximab 375 mg/m2 weekly x 4 doses using standard infusion guidelines. Re-staging was carried out two months after treatment and then every three months during the first three years and every six months thereafter until relapse. Twenty-four of the 25 patients received all of the four planned infusions. One patient stopped treatment after the first infusion because of a dermal vasculitis. Across all follow-up visits the RR was 80% (20/25 patients; 95% CI: 64.32, 95.68) and the rate of CR was 32% (8/25 patients; 95% CI: 13.71, 50.29). Patients with PD at trial registration had higher RR and CR rates compared to relapsed patients (56% vs. 24% and 24% vs. 8% respectively). The RR depends on the number of previous treatments (Table 2). The median RFS was 27 months (95% CI: 15.90, N/A) (Figure 1). Median follow-up time was 27 months. Eight of the 16 patients who achieved CR or PR had a PD. The median RD was 33.6 months. Seven serious adverse events have been recorded: one patient died of cardiac failure one day after the first infusion of rituximab, one patient developed a grade 3 dermal vasculitis and another patient a grade 4 thrombocytopenia. Two patients experienced a basalioma and one patient a prostate cancer during follow-up. One patient died as a result of gastrointestinal bleeding 12 weeks after treatment termination. Most adverse events were grade 1 and 2 expected infusional events that occurred during the first course of rituximab administration.
Rituximab at 375 mg/m2/week x 4 in previously treated HCL has been studied by others. Hagberg and Lundholm7 reported a RR of 64% and Lauria et al.8 50% in a series of 11 and 10 patients respectively. However, Nieva et al. demonstrated a RR of only 25% in 24 CDA-failed patients using the same dose and schedule of ritux-imab.9 This difference may be due to patient selection. The majority of our patients were less pre-treated, having received only one course of CDA. Recently, Thomas et al. published the results of a phase II trial involving 15 patients with relapsed or refractory HCL, using a regimen of eight weekly doses of rituximab at 375 mg/m2. The overall RR was 80%, with 53% CR.10 The higher CR rate suggests that four weekly doses of rituximab may be inadequate to achieve the optimal response. 
Haematologica, Vol 93, Issue 9, 1426-1428 doi:10.3324/haematol.11564
Copyright © 2008 by Ferrata Storti Foundation
Lymphoproliferative Disorders |
Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98)
1 Institute of Medical Oncology, Inselspital Bern
2 SAKK Coordinating Centre, Bern
3 Division of Hematology, Kantonsspital Basel
4 Division of Oncology/Hematology, Kantonsspital St. Gallen
5 Centre of Oncology/Hematology, Kantonsspital Aarau
6 Division of Hematology, Inselspital Berrn
Correspondence: Reinhard Zenhäusern, Institute of Medical Oncology, University of Bern, Inselspital CH 3010 Bern, Switzerland. E-mail:reinhard.zenhaeusern{at}rsv-gnw.ch
Key words: hairy cell leukemia, relapse, rituximab.
We assessed the efficacy of rituximab, 375 mg/m2 weekly x 4, in 26 patients with hairy cell leukemia (HCL) relapsed or progressed after prior 2-chlorodeoxyadenosine (CDA). Overall response rate (RR) was 80%, with 32% complete remission (CR). Median relapse-free-survival (RFS) was 27 months and median remission duration (RD) 33.6 months.
HCL is an indolent B-cell neoplasm. Hairy cells typically coexpress CD11c, CD25 and CD103 antigens in addition to the pan B-cell antigen CD20.1 Patients require treatment for pancytopenia, infections or symptomatic splenomegaly and CDA has emerged as the treatment of choice.2 A single course of CDA produces CR in up to 85% of patients and partial response (PR) in 5–25%.3,4 With longer follow-up, relapses of HCL are common. Goodman et al. reported a 37% relapse rate in 209 patients treated with CDA and had at least seven years of follow-up.5 The RR (CR and PR) after re-treatment with CDA ranges from 60 to 90% but with shorter RD. Bone marrow aplasia, prolonged cytopenias and infections increase with repetitive CDA courses.2 Hairy cells exhibit an especially high CD20 antigen density,6 and the anti-CD20 monoclonal antibody rituximab is considered an attractive treatment option.
We conducted a multicenter phase II trial to investigate rituximab in pre-treated HCL patients of any age who had received at least one previous course of CDA. Diagnosis and assessment of remission was established by morphology including peripheral blood smear and bone marrow examination, supported by a positive tartrate-resistant acid phosphatase (TRAP) stain and characteristic immunophenotyping. Relapse was defined as the reappearance of hairy cells in the bone marrow or as any other new disease manifestations after documented CR. Progressive disease (PD) was defined as >50% increase in the percentage of residual tumor cells, or as >50% increase of residual disease-related organomegaly after documented PR.
Between February 1998 and July 2002, 26 patients were accrued. One patient was not evaluable. Of 25 patients, 24 had classical HCL and one a prolymphocytic sub-type. Pre-treatment consisted of CDA (n=25), splenectomy (n=4), interferon-
(n=9) and alkylating agents (n=2). Nine patients had relapsed and 16 had PD. Patients’ characteristics are summarized in Table 1.
|
View this table: [in a new window] [Download PPT slide] |
Table 1. Patients’ characteristics at study entry (n=25).
|
|
View this table: [in a new window] [Download PPT slide] |
Table 2. Rates of remission.
|
 View larger version (16K): [in a new window] [Download PPT slide] |
Figure 1. Kaplan-Meier curve for relapse-free survival with 95% confidence interval.
|
In conclusion, rituximab has good activity and is well tolerated in patients with HCL. However, the optimal dose and schedule has to be clarified. The efficacy of rituximab as first line treatment for HCL, as treatment of minimal residual disease or in combination with CDA, should be tested in future trials.
References
 TOP References |
|---|
- Cawley JC. Hairy-cell leukaemia: Biology and management. Br J Hematol 1999;106:2-8.[CrossRef][Web of Science][Medline]
- Mey U, Strehl J, Gorschlüter M, Ziske C, Glasmacher A, Pralle H, et al. Advances in the treatment of hairy-cell Leukaemia. Lancet Oncol 2003;4:86-94.[CrossRef][Web of Science][Medline]
- Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up. J Clin Oncol 1997;15:1138-42.
[Abstract/Free Full Text] - Saven A, Burian C, Koziol A, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-26.
[Abstract/Free Full Text] - Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891-6.
[Abstract/Free Full Text] - Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukemias. J Clin Pathol 1998;51:364-9.[Abstract]
- Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001;115:609-11.[CrossRef][Web of Science][Medline]
- Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, et al. Efficacy of anti-CD20 monoclonal antibody, in the treatment of hairy cell leukemia. Haematologica 2001;86:1046-50.
[Abstract/Free Full Text] - Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810-3.
[Abstract/Free Full Text] - Thomas DA, ÒBrien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, et al. Rituximab in relapsed or refractory hairy cell leukaemia. Blood 2003;102:3906-11.
[Abstract/Free Full Text]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||